478 related articles for article (PubMed ID: 29669177)
1. Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype.
Cundy T; Dray M; Delahunt J; Hald JD; Langdahl B; Li C; Szybowska M; Mohammed S; Duncan EL; McInerney-Leo AM; Wheeler PG; Roschger P; Klaushofer K; Rai J; Weis M; Eyre D; Schwarze U; Byers PH
J Bone Miner Res; 2018 Jul; 33(7):1260-1271. PubMed ID: 29669177
[TBL] [Abstract][Full Text] [Related]
2. COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta.
Lindahl K; Barnes AM; Fratzl-Zelman N; Whyte MP; Hefferan TE; Makareeva E; Brusel M; Yaszemski MJ; Rubin CJ; Kindmark A; Roschger P; Klaushofer K; McAlister WH; Mumm S; Leikin S; Kessler E; Boskey AL; Ljunggren O; Marini JC
Hum Mutat; 2011 Jun; 32(6):598-609. PubMed ID: 21344539
[TBL] [Abstract][Full Text] [Related]
3. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.
Rauch F; Lalic L; Roughley P; Glorieux FH
J Bone Miner Res; 2010 Jun; 25(6):1367-74. PubMed ID: 19929435
[TBL] [Abstract][Full Text] [Related]
4. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1.
Ben Amor IM; Roughley P; Glorieux FH; Rauch F
J Bone Miner Res; 2013 Sep; 28(9):2001-7. PubMed ID: 23529829
[TBL] [Abstract][Full Text] [Related]
5. A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases.
Pace JM; Chitayat D; Atkinson M; Wilcox WR; Schwarze U; Byers PH
J Med Genet; 2002 Jan; 39(1):23-9. PubMed ID: 11826020
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta.
Ohata Y; Takeyari S; Nakano Y; Kitaoka T; Nakayama H; Bizaoui V; Yamamoto K; Miyata K; Yamamoto K; Fujiwara M; Kubota T; Michigami T; Yamamoto K; Yamamoto T; Namba N; Ebina K; Yoshikawa H; Ozono K
Osteoporos Int; 2019 Nov; 30(11):2333-2342. PubMed ID: 31363794
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
Kanno J; Saito-Hakoda A; Kure S; Fujiwara I
J Bone Miner Metab; 2018 May; 36(3):344-351. PubMed ID: 28528406
[TBL] [Abstract][Full Text] [Related]
8. A novel COL1A2 C-propeptide cleavage site mutation causing high bone mass osteogenesis imperfecta with a regional distribution pattern.
Rolvien T; Kornak U; Stürznickel J; Schinke T; Amling M; Mundlos S; Oheim R
Osteoporos Int; 2018 Jan; 29(1):243-246. PubMed ID: 28916840
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and the identification of novel mutations of COL1A1 and COL1A2 in 61 Chinese patients with osteogenesis imperfecta.
Zhang H; Yue H; Wang C; Hu W; Gu J; He J; Fu W; Hu Y; Li M; Zhang Z
Mol Med Rep; 2016 Nov; 14(5):4918-4926. PubMed ID: 27748872
[TBL] [Abstract][Full Text] [Related]
10. First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome.
Chen F; Guo R; Itoh S; Moreno L; Rosenthal E; Zappitelli T; Zirngibl RA; Flenniken A; Cole W; Grynpas M; Osborne LR; Vogel W; Adamson L; Rossant J; Aubin JE
J Bone Miner Res; 2014 Jun; 29(6):1412-23. PubMed ID: 24443344
[TBL] [Abstract][Full Text] [Related]
11. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
12. The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta.
Zhang ZL; Zhang H; Ke YH; Yue H; Xiao WJ; Yu JB; Gu JM; Hu WW; Wang C; He JW; Fu WZ
J Bone Miner Metab; 2012 Jan; 30(1):69-77. PubMed ID: 21667357
[TBL] [Abstract][Full Text] [Related]
13. COL1A1 C-propeptide cleavage site mutation causes high bone mass, bone fragility and jaw lesions: a new cause of gnathodiaphyseal dysplasia?
McInerney-Leo AM; Duncan EL; Leo PJ; Gardiner B; Bradbury LA; Harris JE; Clark GR; Brown MA; Zankl A
Clin Genet; 2015 Jul; 88(1):49-55. PubMed ID: 24891183
[TBL] [Abstract][Full Text] [Related]
14. Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization.
Fratzl-Zelman N; Barnes AM; Weis M; Carter E; Hefferan TE; Perino G; Chang W; Smith PA; Roschger P; Klaushofer K; Glorieux FH; Eyre DR; Raggio C; Rauch F; Marini JC
J Clin Endocrinol Metab; 2016 Sep; 101(9):3516-25. PubMed ID: 27383115
[TBL] [Abstract][Full Text] [Related]
15. A novel pathogenic variant at the C-terminal propeptide cleavage site of COL1A1, causing osteogenesis imperfecta with intrafamilial variability.
Lang SH; Gallo RA; Forghani I
Am J Med Genet A; 2022 Jun; 188(6):1885-1889. PubMed ID: 35243755
[TBL] [Abstract][Full Text] [Related]
16. Helical mutations in type I collagen that affect the processing of the amino-propeptide result in an Osteogenesis Imperfecta/Ehlers-Danlos Syndrome overlap syndrome.
Malfait F; Symoens S; Goemans N; Gyftodimou Y; Holmberg E; López-González V; Mortier G; Nampoothiri S; Petersen MB; De Paepe A
Orphanet J Rare Dis; 2013 May; 8():78. PubMed ID: 23692737
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
[TBL] [Abstract][Full Text] [Related]
18. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
Bone; 2016 May; 86():53-7. PubMed ID: 26927310
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genetic analysis in 185 Chinese probands of osteogenesis imperfecta.
Xi L; Zhang H; Zhang ZL
J Bone Miner Metab; 2021 May; 39(3):416-422. PubMed ID: 33070251
[TBL] [Abstract][Full Text] [Related]
20. Molecular heterogeneity in osteogenesis imperfecta type I.
Willing MC; Pruchno CJ; Byers PH
Am J Med Genet; 1993 Jan; 45(2):223-7. PubMed ID: 8456806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
